Panel Discussion – A European Industry & Regulatory Perspective on the Development & Approval of mRNA Medicines
- Uncovering how regulatory provisions can support mRNA medicines’ approval
- Reducing the regulatory approval timeline through platform technology approaches
- Moving towards a harmonized approach for mRNA medicines for the benefit of patients